HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · Retatrutide 20mg + Tirzepatide 40mg
Dual-incretin research blend · research-use
Retatrutide + Tirzepatide blend supply.
Co-formulated 60 mg research vials (retatrutide 20 mg / tirzepatide 40 mg) with per-lot HPLC purity and mass-spec identity documentation, for laboratory and private-label programs.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. Pending finalization, US regulated bulk-substance facilities cannot compound these from bulk substances. Pepti positions GLP-1 compounds for research and private-label brand evaluation worldwide. Read the GLP-1 2026 update →
Retatrutide 20mg + Tirzepatide 40mgHPLC ≥ 99%MS confirmed60mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Retatrutide 20mg + Tirzepatide 40mg |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 60mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Store the lyophilized blend at -20 °C, protected from light and moisture in a desiccated, sealed container. After reconstitution keep at 2-8 °C and use within the validated stability window. Ships under cold chain / with ice packs. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About Retatrutide 20mg + Tirzepatide 40mg.
The product is a physical co-formulation of two incretin-class peptides: retatrutide (LY3437943), a triple agonist at the GLP-1, GIP and glucagon receptors, and tirzepatide (LY3298176), a dual GIP/GLP-1 receptor agonist. Because it is a blend rather than a single molecule it carries no combined CAS, molecular formula or molecular weight; each peptide retains its own identity and is characterized separately on the certificate of analysis.
Documentation
Batch documentation support for Retatrutide 20mg + Tirzepatide 40mg lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the Retatrutide 20mg + Tirzepatide 40mg reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Retatrutide 20mg + Tirzepatide 40mg — frequently asked by B2B buyers.
What exactly is in the Retatrutide 20 mg + Tirzepatide 40 mg vial?
Each 60 mg vial is a physical co-formulation of 20 mg retatrutide and 40 mg tirzepatide presented as a single lyophilized cake. It is not a novel single molecule, so it carries no combined CAS or molecular weight; both peptides are documented individually on the certificate of analysis.
What documentation ships with each lot?
A per-lot certificate of analysis reporting HPLC purity for each peptide and identity confirmation by mass spectrometry (MS), together with appearance, water/residual-solvent and endotoxin (only if specifically ordered and tested) data available on request. Third-party lab verification can be arranged for qualified buyers.
What are the minimum order quantity and available formats?
The catalog format is the 60 mg co-formulated vial (retatrutide 20 mg / tirzepatide 40 mg) at a 50-vial MOQ. Alternative ratios, single-component vials, different fill volumes and bulk lyophilized powder are quoted via RFQ for OEM and private-label programs.
Can the ratio and labeling be customized for private-label?
Yes. As an OEM/private-label supplier we can adjust the retatrutide-to-tirzepatide ratio, vial fill and unbranded labeling and packaging to buyer specification, subject to documentation and destination-market compliance review.
Is this product intended for therapeutic or consumer use?
No. All material is supplied strictly for laboratory research and as a manufacturing input. Retatrutide and tirzepatide are incretin-class compounds subject to regulatory restrictions; the buyer is responsible for compliance in their jurisdiction and must not represent the product for consumer use.
Related compounds